Clinical trial NCT05239858: International Wilson's Disease Patient Registry (iWilson Registry)
Official title: International Wilson's Disease Patient Registry (iWilson Registry)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Wilson's Disease
Keywords: trientine
d-Penicillamine
ATP7B
hepatolenticular degeneration
copper metabolism
zinc
Lead sponsor: Orphalan
Sponsor class: INDUSTRY
Collaborators: name: Ergomed
First posted: 2022-02-15
Enrollment: 500
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The Registry aims to be as inclusive as possible. All patients with WD (adult and paediatric ≥12) who provide informed consent/assent can be included. They will be approached during regular follow up visits for ongoing care of their Wilson's Disease by their primary physician.

Brief summary: Longitudinal, observational, non-interventional, standard of care Registry. Data will be collected from the routinely scheduled WD clinic visits at approximately 6-12 month intervals. At enrolment, in addition to data from the clinic visit, retrospective data will be collected from the diagnostic evaluation and any relevant past medical history and a summary of WD medication history.

Detailed description: This is a retrospective/prospective observational registry without a control group. A standardised collection tool will be utilised to capture and compare data. The registry will use common data elements, guided by a literature review, and expert input from the multidisciplinary advisory board. The SF-12 Health Survey will be requested from patients aged 18 and over at entry to the Registry to provide a snapshot of baseline quality of life assessment in patients with WD. This will enhance generalisability (external validity) and comparability with clinical trial data.

The objectives of the registry are:

1. Natural history of diagnosis and treated WD patients by documentation of observed clinical practice and patient experience
2. Measure, and compare epidemiological and clinical aspects of Wilson Disease (WD) in the participating countries, thereby encouraging the identification of new standards for the management of WD
3. To provide data for epidemiological research and identify groups of patients potentially eligible for multi-centre trials
4. Describe clinical pathways, by documenting standardised examinations and tests used to monitor WD patients including tools to evaluate adherence and compliance to therapies using real-world outcomes.
5. To be more inclusive (heterogeneous patient population; paediatric, adults, elderly) using much broader inclusion criteria and fewer exclusion criteria than commonly used in randomised trials.
6. Longer follow-up compared to RCTs beneficial detecting delayed or long-term benefits or harm and surveillance for rare events of the disease itself or therapies

Patients will be seen as per their usual standard of care visits. Data points of interest for the Registry will be collected. These may include but not limited to: Medical history, Wilson's Disease Diagnosis and Medical History, Genetics, Liver Assessments, Fibrosis Stage, Liver Transplant, Neurological Assessments, Psychological Assessments, Clinical Global Impression of Change Scale (CGIC), Laboratory measurements incl. Urinary Copper Excretion and Free Copper (NCC), Physical Examination, Adverse Reactions and Serious Adverse Reactions documented by physicians

Eligibility criteria: Inclusion Criteria:

1. Patient is able to provide, and has provided, written informed consent/assent
2. Written documentation has been obtained in accordance with the relevant country and local privacy requirements, where applicable, including:

   1. For US sites: Authorization for Use and Release of Health Research Study Information
   2. For EU sites: Data Protection Consent
3. All patients diagnosed with WD including pre-symptomatic individuals and individuals with co-morbidities/diagnoses
4. Any treatments including prescribed and homeopathic/traditional therapies or naive patients on no therapy

Exclusion Criteria:

1. Refusal of informed consent by either patient or their legally acceptable guardian

Primary outcomes:
measure: Describe the natural history of treated WD
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: University Hospital Leuven
city: Bron
country: France
facility: Hospices Civils de Lyon
state: Auvergne-Rhone-Alpes
city: Paris
country: France
facility: HF Adolphe de Rothschild
state: Île-de-France
city: Berlin
country: Germany
facility: Charite-Univeritatsmedizin Berlin Hospital
city: Düsseldorf
country: Germany
facility: Universitatsklinikum Dusseldorf
city: Hannover
country: Germany
facility: Hannover Medical School (MHH)
city: Leipzig
country: Germany
facility: Universitätsklinikum Leipzig
city: Warsaw
country: Poland
facility: Institute of Psychiatry and Neurology
city: Warsaw
country: Poland
facility: The Children's Memorial Health Institute
city: Riyāḑ
country: Saudi Arabia
facility: King Faisal Specialist Hospital in Riyadh
state: Ar Riyāḑ
city: Las Palmas De Gran Canaria
country: Spain
facility: Hospital Universitario GC Dr Negrín
state: Canary Islands
city: Barcelona
country: Spain
facility: University Hospital Clínic de Barcelona, C. de Villarroel
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen del Rocío
city: Valencia
country: Spain
facility: Hospital Universitario Y Politécnico La Fe
city: Leeds
country: United Kingdom
facility: Leeds Teaching Hospitals NHS Trust
city: London
country: United Kingdom
facility: Royal Free Hospital
Study officials:
affiliation: Yale University Hospital, Conneticut
name: Pramod Mistry, PhD
role: STUDY_CHAIR
References: